Cardiovascular

Residual Risk From Remnant Cholesterol and Inflammation Despite Lipid-Lowering Therapy and Association With Incident Peripheral Artery Disease in Type 2 Diabetes.

Liao R, Xiao Z, et al. • Journal of the American Heart Association • 2026

PubMed 42924852 DOI 10.1161/JAHA.126.049813
TL;DR

Among patients with type 2 diabetes receiving lipid-lowering therapy, elevated remnant cholesterol and systemic inflammation (hsCRP) are independently and jointly associated with future peripheral artery disease risk, indicating substantial residual risk beyond managed LDL cholesterol.

Key Findings

Results

Patients with type 2 diabetes on lipid-lowering therapy had a substantial incidence of peripheral artery disease over long-term follow-up.

  • The study included 18,741 UK Biobank participants with type 2 diabetes, free of PAD and on lipid-lowering therapy at baseline.
  • Median follow-up was 13.6 years.
  • Incident PAD occurred in 1223 participants (6.5%).
Results

Elevated remnant cholesterol was independently associated with increased risk of incident PAD.

  • Associations were estimated using multivariable Cox models adjusted for demographic, clinical, metabolic, and treatment-related covariates.
  • Adjustment included LDL cholesterol and baseline coronary artery disease.
  • The abstract states that RC was independently linked to increased PAD risk; specific hazard ratios are not given in the abstract.
Results

Elevated hsCRP was independently associated with increased risk of incident PAD.

  • hsCRP was measured at baseline and modeled with multivariable Cox regression, adjusting for LDL cholesterol and baseline CAD.
  • The association was independent of remnant cholesterol, per the abstract's description of RC and hsCRP each being independently linked to PAD risk.
Results

Participants with concurrent elevations in both remnant cholesterol and hsCRP had the highest risk of incident PAD.

  • The joint-exposure group had higher risk than groups with only one or neither marker elevated.
  • This indicates joint association of remnant lipoproteins and systemic inflammation with PAD risk.
Results

The associations of RC and hsCRP with PAD were robust across multiple sensitivity analyses.

  • Analyses excluded participants with baseline coronary artery disease.
  • Analyses removed events occurring within the first 2 years of follow-up.
  • Analyses excluded individuals with hsCRP >10 mg/L.
  • Competing-risk analyses accounted for death.
  • Results held after further adjustment for detailed lipid-lowering therapy categories.
Conclusions

Remnant cholesterol and inflammation contribute residual PAD risk beyond achieved LDL cholesterol in treated patients with type 2 diabetes.

  • The population was receiving lipid-lowering therapy for primary prevention of PAD.
  • Associations persisted after adjustment for LDL cholesterol.
  • The authors conclude that findings support further strategies targeting both remnant lipoproteins and inflammation.

What This Means

This study followed more than 18,000 people with type 2 diabetes in the UK Biobank who were already taking cholesterol-lowering medication and did not have peripheral artery disease (PAD), a condition in which narrowed arteries reduce blood flow to the legs. Over a median of about 13.6 years, 6.5% of them developed PAD, showing that risk remains even with treatment. People with higher blood levels of remnant cholesterol (cholesterol carried in certain triglyceride-rich particles) or higher levels of hsCRP (a marker of inflammation) were more likely to develop PAD. These links held even after accounting for LDL ("bad") cholesterol, heart disease at baseline, and many other factors. Those with both high remnant cholesterol and high inflammation had the highest risk. The results stayed consistent across several additional checks, such as excluding early cases and people with very high inflammation. This research suggests that LDL cholesterol control alone may not capture all of the PAD risk in people with type 2 diabetes. Remnant cholesterol and inflammation may be additional targets worth investigating. Because this is an observational study, it shows association rather than proving that lowering these markers would prevent PAD.

Have a question about this study?

Presence or severity of Hashimoto's thyroiditis does not influence basal calcitonin levels: observations from CROHT biobank.
Journal of endocrinological investigation • 2022

HT patients of all disease stages preserve Ct production as healthy individuals and there is no need for Ct measurements...
Approach to the Patient: Safety of Growth Hormone Replacement in Children and Adolescents.
The Journal of clinical endocrinology and metabolism • 2022

rhGH therapy has been used for more than 3 decades and data are largely reassuring, yet we still have much to learn abou...
Extended Absorption of Liothyronine from Poly-Zinc-Liothyronine: Results from a Phase 1, Double-Blind, Randomized, and Controlled Study in Humans.
Thyroid : official journal of the American Thyroid Association • 2022

PZL possesses the necessary properties to achieve a much improved T3 pharmacokinetic profile, with ~30% lower Cmax that...
Lipoprotein subtypes after testosterone therapy in transmasculine adolescents.
Journal of clinical lipidology • 2022

Testosterone appears to be a major contributor to differences in lipoprotein profiles, a surrogate for cardiovascular di...
Long-term testosterone undecanoate treatment in the elderly testosterone deficient male: An observational cohort study.
Andrology • 2022

Long-acting testosterone undecanoate treatment in elderly testosterone-deficient patients required more frequent dose ad...
Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism.
Clinical endocrinology • 2022

The Society for Endocrinology commissioned a multidisciplinary guideline to provide all care providers with a comprehens...

Citation

Liao R, Xiao Z, Huang C, Chen L, Liu Y, Wei X, et al.. (2026). Residual Risk From Remnant Cholesterol and Inflammation Despite Lipid-Lowering Therapy and Association With Incident Peripheral Artery Disease in Type 2 Diabetes.. Journal of the American Heart Association. https://doi.org/10.1161/JAHA.126.049813